Items Tagged ‘fulvestrant’

March 17th, 2016

Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer

By

The United States Food and Drug Administration (FDA) has approved Ibrance (palbociclib) to be used with Faslodex (fulvestrant) for women with hormone-positive (HR-positive), human epidermal growth factor receptor-2 (HER2)-negative, metastatic breast cancer that has progressed following prior endocrine (hormone) therapy. The majority of breast cancers are HR-positive. These cancers are stimulated to grow by the […]

View full entry

Tags: approval, Breast Cancer, Faslodex, fda, fulvestrant, HER2-negative, hormone-positive, Ibrance, metastatic, Metastatic Breast Cancer, News, palbociclib


March 9th, 2015

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer

By

Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST study.1 Both overall survival and time to cancer progression were significantly better with Faslodex® than with the current standard of care, Arimidex®. Each year roughly 200,000 U.S. […]

View full entry

Tags: advanced hormone receptor-positive, anastrozole, Arimidex, Breast Cancer, CONFIRM, estrogen receptor antagonist, Faslodex, fulvestrant, Metastatic Breast Cancer, News, Recurrent Breast Cancer


March 5th, 2015

The Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer

By

The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer to be positive for both estrogen receptor (ER) and progesterone receptor (PR) who have previously failed treatment with an aromatase inhibitor. Each year roughly 200,000 U.S. women are […]

View full entry

Tags: Breast Cancer, Faslodex, fulvestrant, hormone-receptor positive, Metastatic Breast Cancer, News, pictilisib, Recurrent Breast Cancer